|
Early Identification of HIV Infection
One of the most important factors that influence patient
outcomes is early identification of HIV infection. Too often
patients present to the clinic or emergency department with
complaints of symptoms consistent with any viral illness.
The most common symptoms of HIV infection include fever, headache,
rash, fatigue, anorexia, pharyngitis, lymphadenopathy, nausea,
vomiting, and diarrhea. If HIV is not suspected or considered
in the differential diagnosis, the patient will be sent home
with the usual instructions: rest, drink plenty of fluids,
and take Tylenol as needed for fever. After about one week
symptoms may resolve with no further treatment, and the patient
can resume their normal activities of daily life. If these
activities include unprotected sex or intravenous drug use,
new cases of HIV infection will occur. The importance of taking
a complete assessment for HIV risk factors can't be overemphasized.
Patients don't usually volunteer personal information unless
asked. Someone coming in for a symptomatic illness may not
think to tell you about a recent divorce or change in relationship.
They will focus on the current problem.
A person who is newly infected with HIV can live eight to
ten years with no distinct symptoms of the illness. They may
have a cold more often than their co-workers or take longer
to recover from an infection, but overall they continue to
look healthy until one day they become very sick and eventually
a diagnosis of HIV infection is made. Patients who are diagnosed
at later stages of the disease usually have Acquired Immune
Deficiency Syndrome or AIDS. This is a condition caused by
HIV which involves symptoms consistent with severe suppression
of the immune system. Patients with AIDS are at risk for developing
opportunistic infections. These infections are caused by pathogens
that are ubiquitous in the environment and only cause illness
when the immune system is too compromised to prevent infection.
Table 2.
Opportunistic Infections Correlated with CD4 Count
Less than 200 cells/mm3
|
- Pneumocystis pneumonia
(PCP)
- Histoplasmosis
- Coccidiomycosis
- Toxoplasmosis
- Miliary/extrapulmonary
TB
- Disseminated cytomegalovirus
- Mycobacterium avium complex
|
Two markers are monitored to determine the prognosis of the
patient with HIV. The first, the T lymphocytes or CD4 count
is a marker of the prognosis of the patient. This provides
a rough estimate of the condition of the immune system. Lower
values are indicative of more severe immune suppression. In
clinical practice, these values are used to determine the
need for antiretroviral therapy and prophylaxis against opportunistic
infections. Usual normal laboratory values for CD4 counts
range from 350- 1200 cells/mm3. When someone reaches 200 cells/mm3
their classification changes from HIV to AIDS. There are other
illnesses that are considered to be AIDS defining and also
change a person's status from HIV to AIDS. These include,
but are not limited to:
- Candidiasis of the lungs, esophagus or trachea
- Cytomegalovirus of the eye
- HIV associated dementia
- Invasive cervical cancer
- Kaposi's sarcoma
- Pneumocystis pneumonia
- Progressive multifocal leukoencephalopathy
- Toxoplasmosis of an internal organ
The second marker is the HIV viral load (VL). This
value is an estimation of the number of copies of HIV in the
body. Since it is estimated rather than an actual number,
it may vary from day to day and/or from morning to night.
Patients should be reassured if this happens.
Antiretroviral
Therapy (ART)
The decision to initiate ART is based on a number of factors.
While there are recommendations for the use of ART meant to
guide treatment, patients should be evaluated personally before
making the decision when to treat and what to treat with.
In many instances, these decisions will be based not only
on medical facts, but also on mental health and socioeconomic
variables. The most efficacious treatment will not be effective
if the person is not adherent with dosing directions. Missing
doses of ART can lead to viral resistance, not only to the
one medication missed, but also to other ART medications in
the same or other classes of drugs. This phenomenon is known
as "cross resistance." Prior to beginning any ART, patients
should be educated about the medication, possible adverse
side effects, the importance of adherence, and potential drug-drug
or drug-food interactions. Whenever possible, regimens should
be chosen to best meet the needs of the individual.
Classes of Antiretroviral Medication
There are currently five classes of antiretroviral medications.
Each class of drugs works to interrupt viral replication at
a distinct step in the process. The use of combination therapy
has been shown to be more effective at controlling the virus
than mono (one medication) or dual therapy (two medications).
Combination therapy increases the sites where drugs can interrupt
the viral replication cycle and effectively lower the viral
load. The five classes of ART are:
- Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Integrase Inhibitors
- Entry/Fusion Inhibitors
There is no known cure for HIV at this time. A person with
an undetectable viral load still has HIV and can still spread
the virus. They are not cured, but they are less likely to
infect someone following exposure than someone with a large
viral load.
How ART Works
Like other viruses, HIV needs to replicate inside another
cell. It has proteins on its surface that are attracted to
receptors on the outside of the CD4 cell's surface. When the
two surfaces meet, they bind which allows entry of the RNA
from the HIV to enter the CD4 cell. This is the point where
fusion and entry inhibitors attempt to interrupt the replication
process by preventing the two cells from binding together.
Table 3.
Fusion/Entry Inhibitors
|
Generic Name
|
Brand Name
|
Date of FDA
Approval
|
Enfuvirtide |
Fuzeon |
2003 |
Maraviroc |
Selzentry |
2007 |
Once the HIV viral capsid enters the cell a viral enzyme
called reverse transcriptase is released. The reverse transcriptase
enzyme has a major role in transcribing viral RNA into DNA,
the genetic material found in human cells. It is at this point
in the replication cycle that nucleoside/ nucleotide and non-nucleoside
reverse transcriptase inhibitors work to interrupt the viral
replication cycle.
Table 4.
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
|
Generic Name
|
Brand Name
|
Date of FDA
Approval
|
Zidovudine |
Retrovir |
1987 |
Didanosine |
Videx |
1991 |
Zalcitabine |
Hivid |
1992 |
Stavudine |
Zerit |
1994 |
Lamivudine |
Epivir |
1995 |
Abacavir |
Ziagen |
1999 |
Tenofovir |
Viread |
2001 |
Emtricitabine |
Emtriva |
2003 |
Non-Nucleoside
Reverse Transcriptase Inhibitors
|
Delavirdine |
Rescriptor |
1997 |
Efavirenz |
Sustiva |
1998 |
Etravirine |
Intelence |
2008 |
Once the viral RNA is transcribed into DNA the genetic material
is transported into the nucleus of the CD4 cell. After this
happens, the viral enzyme integrase facilitates insertion
into the DNA of the CD4 cell so that when the cell replicates
it makes viral cells instead of CD4 cells. In fact, the CD4
cell which previously helped to protect the body from invasion
with harmful organisms is turned into a "viral factory." It
is during this process that the integrase inhibitor attempts
to interrupt the viral replication cycle. The class of integrase
inhibitors is one of the newer classes of ART.
Table 6.
Integrase Inhibitor
|
Generic Name
|
Brand Name
|
Date of FDA
Approval
|
Raltegravir |
Isentress |
2007 |
Viral assembly begins when long strings of proteins are cut
into smaller pieces by the protease enzyme and assembled into
HIV structural elements and enzymes. When this process is
complete, they bud off of the CD4 cell to become new virons.
After maturation, these virons can infect new CD4 cells and
continue the process of immune suppression. Protease inhibitors
target this portion of the process to attempt to interrupt
the viral replication cycle.
Table 7.
Protease Inhibitors
|
Generic Name
|
Brand Name
|
Date of FDA
Approval
|
Saquinavir |
Invirase |
1995 |
Ritonavir |
Norvir |
1996 |
Indinavir |
Crixivan |
1996 |
Nelfinavir |
Viracept |
1997 |
Saquinavir |
Fortovase |
1997 |
Amprenavir |
Agenerase |
1999 |
Atazanavir |
Reyataz |
2003 |
Fosamprenavir |
Lexiva |
2003 |
Tipranavir |
Aptivus |
2005 |
Darunavir |
Prezista |
2006 |
Much research has been conducted in order to understand which
medications have the most efficacy in different circumstances.
As a result of these studies, CDC and other Infectious Disease
organizations have made recommendation on when to begin ART
and what order to use the drugs that are available. Again,
these recommendations are simply guidelines, not solid rules,
and the unique needs of each patient should be assessed prior
to beginning or switching medications.
Table 8.
CDC Recommended Antiretroviral Regimens for Treatment
Naïve Patients (2009)
|
- Non Nucleoside Reverse Transcriptase Inhibitor +
2 Nucleoside/nucleotide Reverse Transcriptase Inhibitors
- One Protease Inhibitor (preferably boosted with
ritonavir) + 2 Nucleoside/nucleotide Reverse Transcriptase
Inhibitors
- One Integrase Inhibitor + 2 Nucleoside/nucleotide
Reverse Transcriptase Inhibitors
|
The viral load is used to monitor the effectiveness
of ART. Once on effective antiretroviral therapy, the HIV
viral load (VL) should be "undetectable." This value is determined
by the type of test used by the laboratory. The most common
values considered to be undetectable can vary from 4 to 400
copies. CD4 and VL laboratory tests are monitored carefully
by the provider and should be checked every three to six months.
If the HIV viral load becomes detectable a discussion should
be held with the patient to determine if all ART is being
taken appropriately at the correct dose and time interval.
The most common reason for the development of viral resistance
is non-adherence. If the patient is non-adherent it is important
to stress the importance of taking ART properly. Studies have
shown that drug resistance can develop if less than 95% of
ART is taken correctly. On occasion, the virus will naturally
mutate to detectable levels. In either case a HIV genotype
should be ordered to determine if genetic mutations have occurred,
and another ART regimen should be initiated if needed based
on these results.
Adherence to ART is important on two levels, for the patient
who is HIV infected, non-adherence can lead to drug resistance
and greatly increase the possibility of death. Drug resistant
HIV viruses are transmitted to newly infected patients from
source patients. A person who is newly diagnosed with HIV/AIDS
can have few if any choices for effective ART, increasing
the possibility of a poor prognosis. The development of multidrug
resistant strains of HIV is a real concern in the field of
medicine and Public Health.
Case Study
1
|
Maria is a 38 year old Hispanic female recently diagnosed
with HIV. She reported that she was probably infected
by her boyfriend, Juan, with whom she had lived for
the past 10 years. She claimed they were in a monogamous
relationship, and so did not worry about using condoms.
Juan had a drug problem before she met him, and had
relapsed several times while they were living together.
His drug of choice is heroin. Juan was diagnosed with
HIV last year after being hospitalized with pneumonia.
He was prescribed ART but he never really recovered
fully from being ill and he died two months ago. After
his death, Maria decided to be tested for HIV.
Maria's PCP explained that her CD4 count was 300/mm3,
and VL was 32,000 copies. Based on the CDC recommendations
she encouraged Maria to start ART. However, before deciding
what medications she should order, a genotype would
be needed to check for viral mutations that could result
in drug resistance. At her next appointment, the PCP
discussed the GT results which indicated probable resistance
to several nucleoside reverse transcriptase inhibitors
and one protease inhibitor. Based on the results they
decided on ART. The PCP carefully explained the dosing,
dietary restrictions, and possible adverse side effects.
She explained that Maria's CD4 and VL would be checked
in one month to determine if the medications were effective,
and if so would be checked every three months to monitor
for any resistance development. She also emphasized
the importance of adherence to all ART. Maria continued
to do very well and her VL remained undetectable.
- What risk factors did Maria have for HIV?
- Why do you think she may not have been tested until
after Juan died?
- Why is it important for Maria to be adherent with
her medications?
Maria was at risk for HIV because her sexual partner
had a past IV drug habit and had relapsed several times
during their relationship. Even if Maria did not use
drugs herself, having unprotected sex with Juan placed
her at risk for infection. Many partners of sick individuals
delay HIV testing until after their partners have died.
This is not a good thing to do, since early detection
and treatment is usually related to a better prognosis.
The main reasons why someone waits to be tested is denial,
not feeling capable of coping with a diagnosis of HIV
while caring for a dying partner, or not wanting their
partner to know they are infected. It is important for
Maria to be adherent to her medication regimen to avoid
resistance development, especially since she was infected
with a strain of virus that already had several mutations.
Theoretically, it could be difficult in the future for
an effective regimen to be identified depending on the
number and type of mutations present.
|
Continue on to HIV
Select Issues
|
|